R & D for endobronchial lavage (EBL) to prevent and treat lung damage from pulmonary chemical agents AOI #15: redirect (repurposing drugs in response to chemical threats)
Ended Definitive Contract Awarded Last action
- Contract number
- 75A50123C00031
- Awardee
-
Isola Therapeutics Inc. UEI M3QDM72NME75
- Awarding agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Obligated
- $749,999
Award facts
- Opportunity
-
- BAA22100SOL00003 Solicitation number
- Contract value 100% obligated
- $749,999.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Minneapolis, MN 55410, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Original award | $749,999 |
About this award
Isola Therapeutics Inc. has been awarded a $749,999 firm fixed-price definitive contract by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to conduct research and development for endobronchial lavage (EBL) as a preventative and therapeutic intervention for lung damage caused by pulmonary chemical agents. The contract, awarded on July 12, 2023, falls under the REDIRECT (Repurposing Drugs in Response to Chemical Threats) initiative, Area of Interest #15, and is being performed in Minneapolis, Minnesota, with a completion date of July 11, 2025. No set-aside designation was used for this procurement.
ASPR's REDIRECT program focuses on identifying existing drugs and therapeutic approaches that can be rapidly adapted to address chemical, biological, radiological, and nuclear threats. This contract represents investment in developing endobronchial lavage techniques—a bronchoscopic procedure involving lung irrigation—as a medical countermeasure for personnel exposed to toxic pulmonary agents. The research aims to establish protocols and evidence supporting EBL's use in both preventing and treating damage from chemical weapons or industrial chemical exposures, potentially supporting emergency preparedness and response capabilities.
Quick answers
Who was awarded contract 75A50123C00031?
75A50123C00031 was awarded to Isola Therapeutics Inc. by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on July 12, 2023.
How much is contract 75A50123C00031 worth?
The government has obligated $749,999 on 75A50123C00031.
Was contract 75A50123C00031 competed?
The extent of competition for 75A50123C00031 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award